EP Patent

EP4568672A2 — Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure

Assigned to BioVentures LLC · Expires 2025-06-18 · 1y expired

What this patent protects

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or redu…

USPTO Abstract

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.

Drugs covered by this patent

Patent Metadata

Patent number
EP4568672A2
Jurisdiction
EP
Classification
—
Expires
2025-06-18
Drug substance claim
No
Drug product claim
No
Assignee
BioVentures LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.